News

Low-dose CT could up early lung cancer detection - at a price


 

He cautioned, however, that the study provides a forecast of cost but does not reflect real-world expenditures.

"This is a model; this is not actual data," he cautioned.

The study was supported by Genentech. Dr. Roth and Dr. Yu reported having no financial disclosures.

Pages

Recommended Reading

AUDIO: Challenges, rewards face creators of pediatric oncofertility clinics
MDedge Hematology and Oncology
Vitamin D deficiency predicts aggressive prostate cancer
MDedge Hematology and Oncology
Panel recommends against low-dose CT for lung cancer in Medicare patients
MDedge Hematology and Oncology
CDC: Policy changes could prevent 100,000 deaths a year
MDedge Hematology and Oncology
Expanded cytoreduction criteria improved survival of carcinoid liver metastases
MDedge Hematology and Oncology
First SEER analysis including HER2 subtype is reported
MDedge Hematology and Oncology
Topical tazarotene did not improve response to imiquimod 5% in lentigo maligna
MDedge Hematology and Oncology
Polyp, adenoma detection rises with Endocuff device
MDedge Hematology and Oncology
Delaying ADT for PSA-only prostate cancer relapse appears safe
MDedge Hematology and Oncology
Obesity increased breast cancer mortality only in premenopausal women
MDedge Hematology and Oncology